Hikma Pharmaceuticals Plc (LON:HIK) has been given an average recommendation of “Hold” by the ten analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is GBX 1,188.90 ($16.00).
Several research firms recently commented on HIK. Numis Securities reaffirmed a “buy” rating and issued a GBX 1,300 ($17.50) price objective on shares of Hikma Pharmaceuticals in a report on Wednesday, December 20th. Jefferies Group raised their price target on shares of Hikma Pharmaceuticals from GBX 1,045 ($14.06) to GBX 1,074 ($14.45) and gave the company a “hold” rating in a report on Monday, December 4th. Morgan Stanley reissued an “equal weight” rating and issued a GBX 1,100 ($14.80) price target on shares of Hikma Pharmaceuticals in a report on Friday, December 1st. Peel Hunt reissued a “hold” rating and issued a GBX 1,390 ($18.71) price target on shares of Hikma Pharmaceuticals in a report on Wednesday, November 15th. Finally, JPMorgan Chase & Co. cut their price target on shares of Hikma Pharmaceuticals from GBX 1,250 ($16.82) to GBX 1,000 ($13.46) and set a “neutral” rating for the company in a report on Friday, November 10th.
Hikma Pharmaceuticals (LON:HIK) opened at GBX 1,143 ($15.38) on Monday. The stock has a market cap of $2,760.00 and a price-to-earnings ratio of 2,198.08. Hikma Pharmaceuticals has a 1-year low of GBX 906.50 ($12.20) and a 1-year high of GBX 2,346 ($31.57).
About Hikma Pharmaceuticals
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.